|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chen ST, Wu MC, Hsu TC, Yen DW, Chang CN,
Hsu WT, Wang CC, Lee M, Liu SH and Lee CC; Health Economics and
Outcome Research Group, National Taiwan University Hospital, :
Comparison of outcome and cost among open, laparoscopic, and
robotic surgical treatments for rectal cancer: A propensity score
matched analysis of nationwide inpatient sample data. J Surg Oncol.
117:497–505. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ali I, Lone MN, Al-Othman ZA, Al-Warthan A
and Sanagi MM: Heterocyclic scaffolds: Centrality in anticancer
drug development. Curr Drug Targets. 16:711–734. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ali I, Wani WA, Haque A and Saleem K:
Glutamic acid and its derivatives: Candidates for rational design
of anticancer drugs. Future Med Chem. 5:961–978. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ali I, Haque A, Saleem K and Hsieh MF:
Curcumin-I Knoevenagel's condensates and their Schiff's bases as
anticancer agents: Synthesis, pharmacological and simulation
studies. Bioorg Med Chem. 21:3808–3820. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ali I, Wani WA, Saleem K and Haque A:
Platinum compounds: A hope for future cancer chemotherapy.
Anticancer Agents Med Chem. 13:296–306. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Miller KD, Siegel RL, Lin CC, Mariotto AB,
Kramer JL, Rowland JH, Stein KD, Alteri R and Jemal A: Cancer
treatment and survivorship statistics, 2016. CA Cancer J Clin.
66:271–289. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Buskermolen M, Cenin DR, Helsingen LM,
Guyatt G, Vandvik PO, Haug U, Bretthauer M and Lansdorp-Vogelaar I:
Colorectal cancer screening with faecal immunochemical testing,
sigmoidoscopy or colonoscopy: A microsimulation modelling study.
BMJ. 367:l5383. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Obaro AE, Burling DN and Plumb AA: Colon
cancer screening with CT colonography: Logistics,
cost-effectiveness, efficiency and progress. Br J Radiol.
91:201803072018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Digoras I, Arrospide A, Portillo I,
Arana-Arri E, Martínez-Indart L, Mar J, de Koning HJ, Lastra R,
Soto-Gordoa M, van der Meulen M and Lansdorp-Vogelaar I: Evaluation
of the colorectal cancer screening Programme in the Basque Country
(Spain) and its effectiveness based on the Miscan-colon model. BMC
Public Health. 18:782017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Arana-Arri E, Idigoras I, Uranga B, Pérez
R, Irurzun A, Gutiérrez-Ibarluzea I, Fraser CG and Portillo I;
EUSKOLON Group, : Population-based colorectal cancer screening
programmes using a faecal immunochemical test: Should faecal
haemoglobin cut-offs differ by age and sex? BMC Cancer. 17:5772017.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
European Colorectal Cancer Screening
Guidelines Working Group, ; von Karsa L, Patnick J, Segnan N, Atkin
W, Halloran S, Lansdorp-Vogelaar I, Malila N, Minozzi S, Moss S, et
al: European guidelines for quality assurance in colorectal cancer
screening and diagnosis: Overview and introduction to the full
supplement publication. Endoscopy. 45:51–59. 2013.PubMed/NCBI
|
|
15
|
Park JS, Kang H, Park SY, Kim HJ, Woo IT,
Park IK and Choi GS: Long-term oncologic after robotic versus
laparoscopic right colectomy: A prospective randomized study. Surg
Endosc. 33:2975–2981. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kim JC, Lee JL, Yoon YS, Kim CW, Park IJ
and Lim SB: Robotic left colectomy with complete mesocolectomy for
splenic flexure and descending colon cancer, compared with a
laparoscopic procedure. Int J Med Robot. 14:e19182018. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
de'Angelis N, Abdalla S, Bianchi G, Memeo
R, Charpy C, Petrucciani N, Sobhani I and Brunetti F: Robotic
versus laparoscopic colorectal cancer surgery in elderly patients:
A propensity score match analysis. J Laparoendosc Adv Surg Tech A.
28:1334–1345. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
National Comprehensive Cancer Network, .
NCCN Clinical Practice Guidelines in Oncology (NCCN
Guidelines®): Colon Cancer, 2016. Available from: URL:.
https://www.nccn.org/professionals/physician_gls/default.aspx
|
|
19
|
Practice Guidelines in Oncology: (NCCN
Guidelines®): Rectal Cancer, 2016. Available from: URL.
https://www.nccn.org/professionals/physician_gls/default.aspx
|
|
20
|
Yao HW, Wu HW and Liu YH: From traditional
population-based approach to individualized precision medicine: The
interpretation of update on The AJCC Colorectal Cancer Staging
System, Eighth Edition. Zhonghua Wai Ke Za Zhi. 55:24–27. 2017.(In
Chinese). PubMed/NCBI
|
|
21
|
Tong GJ, Zhang GY, Liu J, Zheng ZZ, Chen
Y, Niu PP and Xu XT: Comparison of the eighth version of the
American Joint Committee on Cancer manual to the seventh version
for colorectal cancer: A retrospective review of our data. World J
Clin Oncol. 9:148–161. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Liotta LA and Kohn EC: The
microenvironment of the tumour-host interface. Nature. 411:375–379.
2001. View
Article : Google Scholar : PubMed/NCBI
|
|
23
|
Friedl P and Wolf K: Tumour-cell invasion
and migration: Diversity and escape mechanisms. Nat Rev Cancer.
3:362–374. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
24
|
Guo W and Giancotti FG: Integrin
signalling during tumour progression. Nat Rev Mol Cell Biol.
5:816–826. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
25
|
Xiang Z, Mi Y, Jing H, Li L, Jiong SHI,
Baorui L and Xiaoping Q: Expressions of C-MET, COX-2, MSS and Ki-67
in colorectal cancer and correlations with prognosis. J Prev Med
Chin PLA. 36:598–601. 2018.9 (In Chinese).
|
|
26
|
Tong G, Xu W, Zhang G, Liu J, Zheng Z,
Chen Y, Niu P and Xu X: The role of tissue and serum
carcinoembryonic antigen in stages I to III of colorectal cancer-A
retrospective cohort study. Cancer Med. 7:5327–5338. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Tian Y, Ma Z, Chen Z, Li M, Wu Z, Hong M,
Wang H, Svatek R, Rodriguez R and Wang Z: Clinicopathological and
prognostic value of Ki-67 expression in bladder cancer: A
systematic review and meta-analysis. PLoS One. 11:e01588912016.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Arihiro K, Oda M, Ohara M, Kadoya T, Osaki
A, Nishisaka T, Shiroma N and Kobayashi Y: Comparison of visual
assessment and image analysis in the evaluation of Ki-67 expression
and their prognostic significance in immunohistochemically defined
luminal breast carcinoma. Jpn J Clin Oncol. 46:1081–1087. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Clay V, Papaxoinis G, Sanderson B, Valle
JW, Howell M, Lamarca A, Krysiak P, Bishop P, Nonaka D and Mansoor
W: Evaluation of diagnostic and prognostic significance of Ki-67
index in pulmonary carcinoid tumours. Clin Transl Oncol.
19:579–586. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Berlin A, Castro-Mesta JF, Rodriguez-Romo
L, Hernandez-Barajas D, González-Guerrero JF, Rodríguez-Fernández
IA, González-Conchas G, Verdines-Perez A and Vera-Badillo FE:
Prognostic role of Ki-67 score in localized prostate cancer: A
systematic review and meta-analysis. Urologic Oncology, Seminars
and Original Investigations. Elsevier; Amsterdam: 2017, View Article : Google Scholar
|
|
31
|
Niazi MKK, Pennell M, Elkins C, Hemminger
J, Jin M, Kirby S, Kurt H, Miller B, Plocharczyk E and Roth R:
Entropy based quantification of Ki-67 positive cell images and its
evaluation by a reader study. SPIE Medical Imaging. International
Society for Optics and Photonics; Bellingham: pp. p86760I2013
|
|
32
|
Liu Y, Yin W, Yan T, Du Y, Shao Z and Lu
J: The clinical significance of Ki-67 as a marker of prognostic
value and chemosensitivity prediction in hormone-receptor-positive
breast cancer: A meta-analysis of the published literature. Curr
Med Res Opin. 29:1453–1461. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Hashimoto Y, Skacel M, Lavery IC,
Mukherjee AL, Casey G and Adams JC: Prognostic significance of
fascin expression in advanced colorectal cancer: An
immunohistochemical study of colorectal adenomas and
adenocarcinomas. BMC Cancer. 6:2412006. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Dowsett M, Nielsen TO, A'Hern R, Bartlett
J, Coombes RC, Cuzick J, Ellis M, Henry NL, Hugh JC, Lively T, et
al: Assessment of Ki67 in breast cancer: Recommendations from the
International Ki67 in Breast Cancer working group. J Natl Cancer
Inst. 103:1656–1664. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Konsti J, Lundin M, Joensuu H, Lehtimäki
T, Sihto H, Holli K, Turpeenniemi-Hujanen T, Kataja V, Sailas L,
Isola J and Lundin J: Development and evaluation of a virtual
microscopy application for automated assessment of Ki-67 expression
in breast cancer. BMC Clin Pathol. 11:32011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Mohammed ZM, McMillan DC, Elsberger B,
Going JJ, Orange C, Mallon E, Doughty JC and Edwards J: Comparison
of visual and automated assessment of Ki-67 proliferative activity
and their impact on outcome in primary operable invasive ductal
breast cancer. Br J Cancer. 106:383–388. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Klauschen F, Wienert S, Schmitt WD, Loibl
S, Gerber B, Blohmer JU, Huober J, Rüdiger T, Erbstößer E, Mehta K,
et al: Standardized Ki67 diagnostics using automated
scoring-Clinical validation in the GeparTrio Breast Cancer Study.
Clin Cancer Res. 21:3651–3657. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Wei DM, Chen WJ, Meng RM, Zhao N, Zhang
XY, Liao DY and Chen G: Augmented expression of Ki-67 is correlated
with clinicopathological characteristics and prognosis for lung
cancer patients: An up-dated systematic review and meta-analysis
with 108 studies and 14,732 patients. Respir Res. 19:1502018.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Petrelli F, Viale G, Cabiddu M and Barni
S: Prognostic value of different cut-off levels of Ki-67 in breast
cancer: A systematic review and meta-analysis of 64,196 patients.
Breast Cancer Res Treat. 153:477–491. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Luo ZW, Zhu MG, Zhang ZQ, Ye FJ, Huang WH
and Luo XZ: Increased expression of Ki-67 is a poor prognostic
marker for colorectal cancer patients: A meta analysis. BMC Cancer.
19:1232019. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Melling N, Kowitz CM, Simon R, Bokemeyer
C, Terracciano L, Sauter G, Izbicki JR and Marx AH: High Ki67
expression is an independent good prognostic marker in colorectal
cancer. J Clin Pathol. 69:209–214. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Forones NM, Oshima C, Nanogaki S, Tanaka M
and Barbosa V: Determination of proliferative activity using Ki67
and expression of p53 in colorectal cancer. Arq Gastroenterol.
36:122–126. 1999.(In Portuguese). PubMed/NCBI
|
|
43
|
Bacher JW, Flanagan LA, Smalley RL, Nassif
NA, Burgart LJ, Halberg RB, Megid WM and Thibodeau SN: Development
of a fluorescent multiplex assay for detection of MSI-High tumors.
Dis Markers. 20:237–250. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Geiersbach KB and Samowitz WS:
Microsatellite instability and colorectal cancer. Arch Pathol Lab
Med. 135:1269–1277. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Iacopetta B and Watanabe T: Predictive
value of microsatellite instability for benefit from adjuvant
fluorouracil chemotherapy in colorectal cancer. Gut. 55:1671–1672.
2006.PubMed/NCBI
|
|
46
|
Abubakar M, Howat WJ, Daley F, Zabaglo L,
McDuffus LA, Blows F, Coulson P, Raza Ali H, Benitez J, Milne R, et
al: High-throughput automated scoring of Ki67 in breast cancer
tissue microarrays from the Breast Cancer Association Consortium. J
Pathol Clin Res. 2:138–153. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Abubakar M, Orr N, Daley F, Coulson P, Ali
HR, Blows F, Benitez J, Milne R, Brenner H, Stegmaier C, et al:
Prognostic value of automated KI67 scoring in breast cancer: A
centralised evaluation of 8088 patients from 10 study groups.
Breast Cancer Res. 18:1042016. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Gerdes J, Schwab U, Lemke H and Stein H:
Production of a mouse monoclonal antibody reactive with a human
nuclear antigen associated with cell proliferation. Int J Cancer.
31:13–20. 1983. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Gerdes J, Lemke H, Baisch H, Wacker HH,
Schwab U and Stein H: Cell cycle analysis of a cell
proliferation-associated human nuclear antigen defined by the
monoclonal antibody Ki-67. J Immunol. 133:1710–1715.
1984.PubMed/NCBI
|
|
50
|
Bullwinkel J, Baron-Lühr B, Lüdemann A,
Wohlenberg C, Gerdes J and Scholzen T: Ki-67 protein is associated
with ribosomal RNA transcription in quiescent and proliferating
cells. J Cell Physiol. 206:624–635. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Miller I, Min M, Yang C, Tian C, Gookin S,
Carter D and Spencer SL: Ki67 is a graded rather than a binary
marker of proliferation versus quiescence. Cell Rep.
24:1105–1112.e5. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Feng X, Li H, Kornaga EN, Dean M,
Lees-Miller SP, Riabowol K, Magliocco AM, Morris D, Watson PH,
Enwere EK, et al: Low Ki67/high ATM protein expression in malignant
tumors predicts favorable prognosis in a retrospective study of
early stage hormone receptor positive breast cancer. Oncotarget.
7:85798–85812. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Shin IY, Sung NY, Lee YS, Kwon TS, Si Y,
Lee YS, Oh ST and Lee IK: The expression of multiple proteins as
prognostic factors in colorectal cancer: Cathepsin D, p53, COX-2,
epidermal growth factor receptor, C-erbB-2, and Ki-67. Gut Liver.
8:13–23. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Scopa CD, Tsamandas AC, Zolota V,
Kalofonos HP, Batistatou A and Vagianos C: Potential role of bcl-2
and ki-67 expression and apoptosis in colorectal carcinoma: A
clinicopathologic study. Dig Dis Sci. 48:1990–1997. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
De Roock W, Claes B, Bernasconi D, De
Schutter J, Biesmans B, Fountzilas G, Kalogeras KT, Kotoula V,
Papamichael D, Laurent-Puig P, et al: Effects of KRAS, BRAF, NRAS,
and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy
in chemotherapy-refractory metastatic colorectal cancer: A
retrospective consortium analysis. Lancet Oncol. 11:753–762. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Aprile G, Macerelli M, De Maglio G,
Pizzolitto S and Fasola G: The relevance of BRAF and extended ras
mutational analyses for metastatic colorectal cancer patients. OA
Mol Oncol. 1:72013.
|
|
57
|
Kislitsin D, Lerner A, Rennert G and Lev
Z: K-ras mutations in sporadic colorectal tumors in Israel: Unusual
high frequency of codon 13 mutations and evidence for
nonhomogeneous representation of mutation subtypes. Dig Dis Sci.
47:1073–1079. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Fransén K, Klintenäs M, Osterström A,
Dimberg J, Monstein HJ and Söderkvist P: Mutation analysis of the
BRAF, ARAF and RAF-1 genes in human colorectal adenocarcinomas.
Carcinogenesis. 25:527–533. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Wong R and Cunningham D: Using predictive
biomarkers to select patients with advanced colorectal cancer for
treatment with epidermal growth factor receptor antibodies. J Clin
Oncol. 26:5668–5670. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Sartore-Bianchi A, Martini M, Molinari F,
Veronese S, Nichelatti M, Artale S, Di Nicolantonio F, Saletti P,
De Dosso S, Mazzucchelli L, et al: PIK3CA mutations in colorectal
cancer are associated with clinical resistance to EGFR-targeted
monoclonal antibodies. Cancer Res. 69:1851–1857. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Shia J, Schultz N, Kuk D, Vakiani E,
Middha S, Segal NH, Hechtman JF, Berger MF, Stadler ZK, Weiser MR,
et al: Morphological characterization of colorectal cancers in The
Cancer Genome Atlas reveals distinct morphology-molecular
associations: Clinical and biological implications. Mod Pathol.
30:599–609. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Song GA, Deng G, Bell I, Kakar S,
Sleisenger MH and Kim YS: Mucinous carcinomas of the colorectum
have distinct molecular genetic characteristics. Int J Oncol.
26:745–750. 2005.PubMed/NCBI
|
